title: CBP/p300 acetyltransferase activity in hematologic malignancies.
abstract: CREB binding protein (CBP) and p300 are critical regulators of hematopoiesis through both their transcriptional coactivator and acetyltransferase activities. Loss or mutation of CBP/p300 results in hematologic deficiencies in proliferation and differentiation as well as disruption of hematopoietic stem cell renewal and the microenvironment. Aberrant lysine acetylation mediated by CBP/p300 has recently been implicated in the genesis of multiple hematologic cancers. Understanding the effects of disrupting the acetyltransferase activity of CBP/p300 could pave the way for new therapeutic approaches to treat patients with these diseases.
authors.affiliation: Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Ritika
authors.initials: R
authors.lastname: Dutta
authors.affiliation: Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Bruce
authors.initials: B
authors.lastname: Tiu
authors.affiliation: Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: kmsakamo@stanford.edu.
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Sakamoto
mesh_terms: D000107:Acetylation; D050882:CREB-Binding Protein / Q000235:genetics*; D050881:E1A-Associated p300 Protein / Q000235:genetics*; D019337:Hematologic Neoplasms / Q000235:genetics* / Q000473:pathology; D006410:Hematopoiesis / Q000235:genetics; D006801:Humans; D008239:Lysine / Q000378:metabolism; D009154:Mutation; D014158:Transcription, Genetic
chemical_list: D050882:CREB-Binding Protein; C494363:CREBBP protein, human; D050881:E1A-Associated p300 Protein; C494360:EP300 protein, human; D008239:Lysine
keywords: CBP; CREB-binding protein; Hematologic malignancies; Lysine acetyltransferase activity; Targeted therapy; p300